Navigation Links
Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
Date:6/29/2011

e antigens to differ slightly from the native protein. In humans, this novel approach may help the body's immune system to overcome its "self-tolerance" of cancerous cells created in the body by recognizing these cells as being foreign and mounting an immune response to clear these cells.

Inovio is currently manufacturing clinical grade INO-5150 with the goal of launching its planned Phase I study in mid-2012.

Dr. Kim said: "The immune response data achieved by our SynCon™ prostate cancer vaccine in this large animal study is exceptional. It reinforces the repeatedly and consistently strong, long-lasting immune responses achieved by Inovio's DNA vaccine platform against multiple cancers as well as other diseases. We are optimistic about the potential of this therapeutic vaccine in our planned prostate cancer human study and broadly speaking for cancers in general, including our currently progressing cervical cancer and leukemia Phase II clinical studies."

The development of a new treatment for prostate cancer would be a significant medical advance given that present treatment options (surgery, radiation and hormone deprivation), while somewhat effective, all carry deleterious side effects and often do not confer long-term cure. Across the United States, there were 218,000 new cases of prostate cancer and more than 32,000 deaths in 2010.

Inovio's Cancer Portfolio...Into Phase II and Diverse Cancer TypesInovio's SynCon™ DNA vaccine technology has created the potential for a new generation of cancer vaccines. Inovio is moving forward with two DNA vaccines in Phase II development:

  • VGX-3100, Inovio's proprietary DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV); and,
  • pWT1, a DNA vaccine for treating acute and chronic myeloid leukemia (CML and AML). Inovio is also working with partners on this DNA vaccine using its electroporation delivery technology.

  • '/>"/>

    SOURCE Inovio Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
    2. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
    3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
    4. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
    5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    6. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
    7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
    8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
    9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
    10. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
    11. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... Biovista Inc. freut sich, ... 2015 bekanntgeben zu können. Hierbei handelt es sich ... Biovista unterstützt mit seiner Möglichkeit der Analyse ... Krankheiten als denen, für die ein Medikament ursprünglich ... Team bei der Wylder Nation Foundation bei der ...
    (Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Services Staff members will be attending Pharma Ed Resources upcoming educational seminar ... group of industry leading speakers, this timely conference will provide Updates & Case ...
    (Date:9/2/2015)... Diego, CA (PRWEB) , ... September 02, 2015 ... ... troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to analysis ... detailed views of fascinating events that go by too quickly to process with ...
    (Date:9/1/2015)... Swecure, ein Biotechnologieunternehmen, ... Entwicklung neuartiger Therapien für Störungen des Immunsystems ... konzentriert, erhält vom US Patent and Trademark ... patentiert wird. Das Medikament basiert auf einem ... und Entzündungen vorbeugt.   Das Medikament, ...
    Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
    ... October 5 , - A New Miniaturized PCR ... Price of QuanTyper(TM) Without Loss of Performance, - ... AlphaHelix (Ticker: ALPH) has in a very ... for lower,instrument prices. This was made possible through know-how obtained during,the ...
    ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
    ... ... Global packaging specialist,Sepha, says the increased pressure to reduce costs and ... and blister-scanning technologies. While blisterpacks offer pharmaceutical companies a simple ... often makes it difficult to either test for leaks or recover ...
    Cached Biology Technology:AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering 2Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering 3
    (Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
    (Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
    (Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
    Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
    ... LyondellBasell announced the following schedule and contact information for a teleconference on financial results through the ... , Monday, August 16, 2010 , ... Doug Pike, Vice President, Investor Relations , ... 800-369-1176 , London: 0800-279-9630 , ...
    ... Georgia Institute of Technology are using funding from the ... as ARPA-E to pursue two different, but related, ... of coal-burning power plants. Power plants ... the United States each year. The researchers will ...
    ... URBANA A dog,s indiscriminate taste is not always ... gastrointestinal infections and consequent ailments such as diarrhea and ... gastrointestinal diseases such as inflammatory bowel diseases that are ... by intestinal bacteria. Researchers at the University ...
    Cached Biology News:Teleconference Alert: LyondellBasell Reviews Second Quarter 2010 Financial Results 2ARPA-E funding supports research on carbon dioxide removal from flue gases 2ARPA-E funding supports research on carbon dioxide removal from flue gases 3ARPA-E funding supports research on carbon dioxide removal from flue gases 4Illinois researchers use pyrosequencing to study canine intestinal bacteria 2
    PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
    Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
    sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
    Recombinant Mouse MMP-9, CF...
    Biology Products: